Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240383 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study With LT, Monotherapy, PPAR
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,260
- Enrollment target
NCT00240383: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00240383 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (847% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240383, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00240383 record still lists
NCT00240383 is an interventional study that assigns participants to a tested intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (847% higher).
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00240383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00240383 about?
NCT00240383 is a clinical study titled "Dose Ranging Study With LT, Monotherapy, PPAR". A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
What is the current status of trial NCT00240383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,260 participants. The study started on 2002-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00240383?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00240383?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00240383's enrollment target sits among peer trials
1,260 15th of 2000 higher than 1,985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia